NIVOREN GETUG-AFU 26 translational study: CD8 infiltration and PD-L1 expression are associated with outcome in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N)

MLA

Sylvie Chabaud, et al. “NIVOREN GETUG-AFU 26 Translational Study: CD8 Infiltration and PD-L1 Expression Are Associated with Outcome in Patients (Pts) with Metastatic Clear Cell Renal Cell Carcinoma (MccRCC) Treated with Nivolumab (N).” Annals of Oncology, vol. 30, Oct. 2019, pp. v360–61. EBSCOhost, https://doi.org/10.1093/annonc/mdz249.008.

APA

Sylvie Chabaud, Marine Gross-Goupil, Benoit Beuselinck, B. Laguerre, Laurence Albiges, C. Dalban, Florence Tantot, J. Barros Monteiro, Delphine Borchiellini, Christine Chevreau, Nathalie Chaput, Wolf-Hervé Fridman, Sylvie Negrier, Nathalie Rioux-Leclercq, Bernard Escudier, Catherine Sautès-Fridman, I. Colina-Moreno, Antoine Bougoüin, Salem Chouaib, & Yann-Alexandre Vano. (2019). NIVOREN GETUG-AFU 26 translational study: CD8 infiltration and PD-L1 expression are associated with outcome in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N). Annals of Oncology, 30, v360–v361. https://doi.org/10.1093/annonc/mdz249.008

Chicago

Sylvie Chabaud, Marine Gross-Goupil, Benoit Beuselinck, B. Laguerre, Laurence Albiges, C. Dalban, Florence Tantot, et al. 2019. “NIVOREN GETUG-AFU 26 Translational Study: CD8 Infiltration and PD-L1 Expression Are Associated with Outcome in Patients (Pts) with Metastatic Clear Cell Renal Cell Carcinoma (MccRCC) Treated with Nivolumab (N).” Annals of Oncology 30 (October): v360–61. doi:10.1093/annonc/mdz249.008.